Key result
Low-molecular-weight heparins show insufficient evidence to support standard chronic stroke prevention in AF.
Why the study?
Low-molecular-weight heparins are still used in selected clinical scenarios in atrial fibrillation despite limited robust evidence for their long-term use in stroke prevention.
Does low-molecular-weight heparin reduce thromboembolic complications compared to standard oral anticoagulation in patients with atrial fibrillation?
Does low-molecular-weight heparin reduce thromboembolic complications compared to standard oral anticoagulation in patients with atrial fibrillation?
LMWHs should not be routinely used for chronic stroke prevention in patients with atrial fibrillation, but they remain an important temporary option for bridging therapy, acute hospitalizations, and complex cancer-associated scenarios when oral anticoagulants are contraindicated.
Introduction Atrial fibrillation (AF) is associated with a significantly increased risk of thromboembolic complications, including ischaemic stroke. Despite the dominant role of oral anticoagulants, low-molecular-weight heparins (LMWHs) are still used in selected clinical scenarios. Aim The aim of this review was to summarise the current clinical role of LMWHs in atrial fibrillation, with particular emphasis on available evidence, practical limitations and selected complex clinical scenarios. Methods A review based on the analysis of available clinical trials, guidelines, and pharmacological data. Results Low-molecular-weight heparins are used primarily for bridging therapy and in situations where oral anticoagulation is temporarily contraindicated or not feasible. However, robust evidence supporting the long-term use of LMWHs for stroke prevention in atrial fibrillation remains limited. Conclusion Low-molecular-weight heparins should not be considered standard chronic therapy for atrial fibrillation. Further studies are needed to better define optimal anticoagulation strategies in patients with atrial fibrillation, particularly in complex clinical settings such as active cancer and thrombocytopenia.
No takes yet. Share an insight, caveat, or question.
Mędrek et al. (2026) conducted a review in Atrial fibrillation. Low-molecular-weight heparins (LMWHs) vs. Oral anticoagulants, aspirin, or no bridging was evaluated. Low-molecular-weight heparins should not be considered standard chronic therapy for stroke prevention in atrial fibrillation due to limited robust evidence, despite utility in bridging therapy or complex clinical scenarios.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: